Masahiro Fukuoka

Q: What Schools Are Affiliated With Masahiro Fukuoka

Masahiro Fukuoka is affiliated with the following schools: Hyogo College of Medicine, University of Toronto, Tokyo Medical University, Kyoto University, Heidelberg University, Hokkaido University, Yasuda Women's University, University of Tokyo, Chinese University of Hong Kong

Masahiro Fukuoka's AcademicInfluence.com Rankings

Masahiro Fukuoka

Philosophy

#7298

World Rank

#10491

Historical Rank

Logic

#4355

World Rank

#5638

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Masahiro Fukuoka's Degrees

PhD Pharmaceutical Sciences University of Tokyo
Doctorate Medicine University of Tokyo

Why Is Masahiro Fukuoka Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Masahiro Fukuoka's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. (2009) (6176)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. (2010) (3811)
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. (2003) (2937)
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. (1999) (1444)
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). (2011) (1443)
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. (2002) (1305)
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. (2014) (645)
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. (2005) (618)
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. (2002) (617)
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. (2006) (610)
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab (2011) (577)
CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. (1992) (453)
A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. (1992) (439)
Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. (1991) (431)
Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. (2008) (359)
Gefitinib — a novel targeted approach to treating cancer (2004) (354)
Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). (2006) (354)
Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. (2008) (335)
Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. (2006) (335)
Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. (1991) (286)
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. (2013) (286)
Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. (2003) (271)
A prospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancer. The Japan Lung Cancer Photodynamic Therapy Study Group. (1993) (250)
Phase II clinical study of photodynamic therapy using mono-L-aspartyl chlorin e6 and diode laser for early superficial squamous cell carcinoma of the lung. (2003) (247)
Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. (2010) (232)
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403) (2008) (205)
Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer (2012) (205)
Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with EGFR Mutations (2009) (197)
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival (2017) (189)
Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. (2009) (185)
Final results from a phase II trial of ZD1839 ("Iressa") for patients with advanced non-small-cell lung cancer (IDEAL 1) (2002) (178)
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). (2004) (177)
Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. (2012) (175)
Skeletal metastases in non-small cell lung cancer: a retrospective study. (2007) (171)
Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. (1998) (171)
Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors (2009) (166)
Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). (2010) (159)
Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). (2012) (159)
Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. (2010) (159)
Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer (2003) (158)
Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. (2007) (157)
CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. (1992) (148)
Radiosensitizing Effect of YM155, a Novel Small-Molecule Survivin Suppressant, in Non–Small Cell Lung Cancer Cell Lines (2008) (144)
Curcumin prevents and reverses murine cardiac hypertrophy. (2008) (136)
Negative regulation of forkhead transcription factor AFX (Foxo4) by CBP-induced acetylation. (2003) (128)
Health-Related Quality-of-Life in a Randomized Phase III First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients from Asia with Advanced NSCLC (IPASS) (2011) (128)
Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS). (2009) (124)
Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study (2007) (121)
Efficacy and Safety of Two Doses of Pemetrexed Supplemented with Folic Acid and Vitamin B12 in Previously Treated Patients with Non-Small Cell Lung Cancer (2008) (112)
Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation. (2007) (109)
A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903) (2012) (107)
Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. (1993) (104)
Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status (2008) (102)
Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance. (2004) (102)
O-242 Gefitinib (‘Iressa’, ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer in IDEAL 1 and 2: tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone (2003) (102)
Regulatory T Cells Protect Mice Against Coxsackievirus-Induced Myocarditis Through the Transforming Growth Factor &bgr;–Coxsackie-Adenovirus Receptor Pathway (2010) (101)
EGFR mutation in gefitinib-responsive small-cell lung cancer. (2006) (100)
p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung. (1997) (99)
Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. (1994) (98)
[A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group]. (1991) (96)
Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. (1998) (96)
A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer (2008) (88)
Enhancement of Tumor Radio‐response by Irinotecan in Human Lung Tumor Xenografts (1997) (87)
Gelsolin Regulates Cardiac Remodeling After Myocardial Infarction Through DNase I–Mediated Apoptosis (2009) (84)
EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. (2006) (83)
TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non–Small Cell Lung Cancer with an EGFR Mutation (2010) (82)
Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin (2006) (81)
Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer. (2005) (81)
Enhanced Anticancer Effect of the Combination of BIBW2992 and Thymidylate Synthase–Targeted Agents in Non–Small Cell Lung Cancer with the T790M Mutation of Epidermal Growth Factor Receptor (2010) (79)
Enhanced Antitumor Efficacy of a Combination of CPT‐11, a New Derivative of Camptothecin, and Cisplatin against Human Lung Tumor Xenografts (1993) (79)
Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non-small Cell Lung Cancer: A Phase II Study (2008) (78)
Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group. (1998) (77)
Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay. (1995) (76)
Cathepsin‐L Ameliorates Cardiac Hypertrophy Through Activation of the Autophagy–Lysosomal Dependent Protein Processing Pathways (2013) (73)
A randomized phase III study of irinotecan and cisplatin (CP) versus etoposide and cisplatin (EP) in extensive-disease small-cell lung cancer (ED-SCLC): Japan Clinical Oncology Group Study (JCOG 9511) (2000) (72)
A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin. (1991) (70)
Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. (2006) (70)
De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in EGFR Mutation-Positive Patients with Non-small Cell Lung Cancer (2010) (70)
Postmarketing Surveillance Study of Erlotinib in Japanese Patients With Non–Small-Cell Lung Cancer (NSCLC): An Interim Analysis of 3488 Patients (POLARSTAR) (2012) (70)
Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs (2010) (70)
A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group. (1998) (70)
Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase (2008) (69)
Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. (1994) (68)
Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib‐resistant non‐small cell lung cancer cells with acquired MET amplification (2010) (67)
294 A randomized phase III study of concurrent versus sequential thoracic radiotherapy (TRT) in combination with mitomycin (M), vindesine (V), and cisplatin (P) in unresectable stage III non-small cell lung cancer (NSCLC): Preliminary analysis (1997) (67)
Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung cancer (NSCLC): Survival follow-up results of JO25567. (2018) (66)
Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer. (2004) (63)
Results of a randomized phase III study to compare the overall survival of gefitinib (IRESSA) versus docetaxel in Japanese patients with non-small cell lung cancer who failed one or two chemotherapy regimens (2007) (63)
Photodynamic Therapy for Cancers: A Clinical Trial of Porfimer Sodium in Japan (1993) (62)
Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells. (2010) (62)
Randomized phase III study of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Results of West Japan Thoracic Oncology Group trial (WJTOG (2008) (61)
Irinotecan (CPT-11): pharmacology and clinical applications. (1996) (60)
Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer (2014) (59)
CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. (1997) (59)
[Phase I clinical trial of RP 56976 (docetaxel) a new anticancer drug]. (1994) (59)
Inhibition of Insulin-Like Growth Factor 1 Receptor by CP-751,871 Radiosensitizes Non–Small Cell Lung Cancer Cells (2009) (58)
A comparative trial of LC9018 plus doxorubicin and doxorubicin alone for the treatment of malignant pleural effusion secondary to lung cancer (1991) (58)
Phase I study of E7010 (1998) (58)
Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase. (1996) (57)
A phase I study of GW572016 in patients with solid tumors. (2004) (57)
Personalized medicine and proteomics: lessons from non-small cell lung cancer. (2007) (57)
Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. (2011) (57)
Cathepsin-L contributes to cardiac repair and remodelling post-infarction. (2011) (57)
Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients (2016) (56)
Case‐Control Study for Lung Cancer and Cigarette Smoking in Osaka, Japan: Comparison with the Results from Western Europe (1994) (55)
Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort. (2018) (54)
Photodynamic therapy and/or external beam radiation therapy for roentgenologically occult lung cancer (1994) (54)
A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours (2006) (52)
Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer. (1998) (52)
Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan. (2002) (51)
Randomized controlled study of adjuvant immunotherapy with Nocardia rubra cell wall skeleton for inoperable lung cancer. (1983) (51)
Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Non–small cell Lung Cancer Cell Lines with MET Amplification (2009) (51)
Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515. (2007) (50)
Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer (1999) (50)
Cisplatin-based combination chemotherapy for elderly patients with non-small-cell lung cancer (1997) (50)
Gefitinib in non-small cell lung cancer (2005) (49)
Prognostic factors and prognostic staging system for small cell lung cancer. (1997) (49)
Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk (2007) (49)
Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): Meta-analysis from four clinical trials. (2009) (48)
Identification of c-Src as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to c-Src Inhibition (2010) (48)
Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902. (2006) (48)
The Four-Arm Cooperative Study (FACS) for advanced non-small-cell lung cancer (NSCLC). (2004) (48)
Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small-cell lung cancer. (2000) (47)
Mutational analysis of the β-tubulin gene in lung cancer (2002) (47)
A Phase I intermittent dose-escalation trial of ZD1839 (IressaTM) in Japanese patients with solid malignant tumors (2000) (47)
Phase III, randomized, open‐label, first‐line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non‐small‐cell lung cancer: evaluation of patients recruited from mainland China (2012) (45)
Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). (2014) (43)
A randomized study of cisplatin versus cisplatin plus vindesine for non‐small cell lung carcinoma (1991) (43)
Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non–small cell lung cancer (2009) (42)
Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study. (2013) (42)
Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage IIIB or IV non-small-cell lung cancer (NSCLC). The Japan Vinorelbine Lung Cancer Cooperative Study Group. (1996) (42)
The quality of life questionnaire for cancer patients treated with anticancer drugs (QOL-ACD): Validity and reliability in Japanese patients with advanced non-small-cell lung cancer (2002) (41)
Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer (2001) (41)
Establishment and characterization of 20 human non-small cell lung cancer cell lines in a serum-free defined medium (ACL-4). (1991) (41)
Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803) (2004) (40)
Prognostic significance of telomeric repeat length alterations in pathological stage I-IIIA non-small cell lung cancer. (2000) (40)
Chemotherapy in small cell lung cancer: a consensus report (1989) (40)
Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study. (2020) (39)
Point mutations of the topoisomerase IIalpha gene in patients with small cell lung cancer treated with etoposide. (1996) (39)
S-1 Plus Cisplatin with Concurrent Radiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Multi-Institutional Phase II Trial (West Japan Thoracic Oncology Group 3706) (2011) (39)
Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. (2017) (39)
Clinical Usefulness of CYFRA Assay in Diagnosing Lung Cancer: Measurement of Serum Cytokeratin Fragment (1994) (38)
Synergistic Antitumor Effect of S-1 and HER2-Targeting Agents in Gastric Cancer with HER2 Amplification (2010) (38)
Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non‐small cell lung cancer (2008) (38)
Relationship between the Pharmacokinetics of Irinotecan and Diarrhea during Combination Chemotherapy with Cisplatin (1995) (38)
Induction of MRP5 and SMRP mRNA by adriamycin exposure and its overexpression in human lung cancer cells resistant to adriamycin (2001) (38)
Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study. (2000) (37)
[An early phase II study of CPT-11 in primary lung cancer]. (1991) (37)
Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer. (2010) (36)
Endpoints for multimodal clinical trials in stage III non-small cell lung cancer (NSCLC): a consensus report. (1994) (36)
Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancer (2001) (36)
Prognostic significance of hTERT expression in non-small cell lung cancer. (2000) (35)
Phase II Study of 3-Hour Infusion of Paclitaxel in Patients with Previously Untreated Stage III and IV Non-Small Cell Lung Cancer (1997) (35)
Efficacy and safety of erlotinib in elderly patients in the phase IV POLARSTAR surveillance study of Japanese patients with non-small-cell lung cancer. (2014) (34)
Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer (2005) (34)
Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel. (2009) (34)
Lung Cancer Risk among Exsmokers (1991) (34)
Intrapleural Administration of Cisplatin and Etoposide to Treat Malignant Pleural Effusions in Patients with Non-Small Cell Lung Cancer (1999) (33)
Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer (2005) (33)
Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity. (2010) (33)
Efficacy Differences of Pemetrexed by Histology in Pretreated Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Review of Results from an Open-Label Randomized Phase II Study (2009) (32)
Predict, prevent and personalize: Genomic and proteomic approaches to cardiovascular medicine. (2007) (32)
Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses (2007) (32)
Identification of thymidylate synthase as a potential therapeutic target for lung cancer (2010) (31)
Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer (2006) (31)
Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study (2007) (31)
Early palliative intervention for patients with advanced cancer. (2013) (31)
Survival and prognostic factors in lung cancer patients treated in phase I trials: Japanese experience. (1999) (31)
Phase I/II trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung Cancer (WJTOG-0002). (2007) (30)
S-1: a new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer. (2009) (30)
Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402). (2012) (30)
Systemic Therapy of Bronchioloalveolar Carcinoma: Results of the First IASLC/ASCO Consensus Conference on Bronchioloalveolar Carcinoma (2006) (30)
ASP8273, a mutant-selective irreversible EGFR inhibitor in patients (pts) with NSCLC harboring EGFR activating mutations: Preliminary results of first-in-human phase I study in Japan. (2015) (29)
Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI). (2003) (28)
The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations (2010) (28)
[A phase II clinical study of cis-diammine glycolato platinum, 254-S, for primary lung cancer]. (1992) (27)
Phase I study of TZT‐1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks (2009) (27)
Brain metastasis in malignant pleural mesothelioma. (1997) (27)
A phase II study of topotecan in patients with relapsed small-cell lung cancer. (2003) (27)
Amrubicin for non-small-cell lung cancer and small-cell lung cancer (2007) (26)
Proteomic Biomarkers for Acute Interstitial Lung Disease in Gefitinib-Treated Japanese Lung Cancer Patients (2011) (25)
A randomized phase III study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer. (2014) (25)
Randomized, open-label, multicenter phase II study of bevacizumab in combination with carboplatin and paclitaxel in chemotherapy-naive Japanese patients with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC): JO19907. (2016) (25)
Prognostic significance of serum p53 antibodies in squamous cell carcinoma of the lung. (1997) (25)
Lung Cancer Incidence Rate for Male Ex‐smokers According to Age at Cessation of Smoking (1993) (25)
CODE chemotherapy with or without recombinant human granulocyte colony-stimulating factor in extensive-stage small cell lung cancer. (1992) (25)
Dual-phase response model for bronchial asthma. (2000) (25)
A Multi-Institution Phase I/II Trial of Triweekly Regimen with S-1 Plus Cisplatin in Patients with Advanced Non-small Cell Lung Cancer (2010) (24)
Limited-stage small cell lung cancer: local failure after chemotherapy and radiation therapy. (1998) (24)
Pooled analysis of S-1 trials in non-small cell lung cancer according to histological type. (2010) (24)
Phase II Study of Combination Therapy with S-1 and Irinotecan for Advanced Non–Small Cell Lung Cancer: West Japan Thoracic Oncology Group 3505 (2008) (24)
Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience (2007) (24)
Phase I dose-escalation and pharmacokinetic trial of lapatinib (GW572016), a selective oral dual inhibitor of ErbB-1 and -2 tyrosine kinases, in Japanese patients with solid tumors. (2008) (23)
Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease. (2010) (23)
Correlation among the Indices of High-Resolution Computed Tomography, Pulmonary Function Tests, Pulmonary Perfusion Scans and Exercise Tolerance in Cases of Chronic Pulmonary Emphysema (2002) (23)
55 Phase II study of amrubicin (SM-5887), a novel 9-amino-anthracycline, in previously untreated patients with extensive-stage small-cell lung cancer (ES-SCLC): A trial of the west Japan lung cancer group (1997) (23)
Activity of gemcitabine in non-small-cell lung cancer: results of the Japan gemcitabine group (A) phase II study (1997) (23)
The effect of theophylline on blood and sputum eosinophils and ECP in patients with bronchial asthma. (1998) (23)
Correlation of molecular markers including mutations with clinical outcomes in advanced non small cell lung cancer (NSCLC) patients (pts) treated with gefitinib, chemotherapy or chemotherapy and gefitinib in IDEAL and INTACT clinical trials (2005) (23)
Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial. (2014) (23)
Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer (2002) (22)
Ritterazine B, a new cytotoxic natural compound, induces apoptosis in cancer cells (2003) (22)
Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): A model for prospective comparison of cooperative group trials (2004) (21)
Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine. (2005) (21)
The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo (2007) (21)
Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group (2014) (20)
[Subset analysis of data in the Japanese patients with NSCLC from IDEAL 1 study on gefitinib]. (2004) (20)
Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non-small-cell lung cancer: long-term follow-up results. Japan Clinical Oncology Group Protocol 8902. (2000) (20)
The anti‐EGFR monoclonal antibody blocks cisplatin‐induced activation of EGFR signaling mediated by HB‐EGF (2008) (20)
Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders (2005) (20)
Small cell carcinoma of the lung and its histological origin. Report of a case. (1979) (20)
Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients. (2008) (20)
Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent d-19575 (glufosfamide) in patients with solid tumors (2009) (19)
Phase II Trial of Amrubicin for Second-Line Treatment of Advanced Non-small Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG0401) (2010) (19)
Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer (2004) (19)
Association between baseline pulmonary status and interstitial lung disease in patients with non-small-cell lung cancer treated with erlotinib--a cohort study. (2014) (19)
Detection of large cell component in small cell lung carcinoma by combined cytologic and histologic examinations and its clinical implication (1992) (19)
Lung cancer working group report. (2010) (19)
P-615 Phase II trials of gefitinib (‘Iressa’, ZD1839): rapid and durable objective responses in patients with advanced non-small-cell lung cancer (IDEAL 1 and IDEAl 2) (2003) (19)
Mutational analysis of the beta-tubulin gene in lung cancer. (2002) (19)
Evaluation of high‐dose etoposide combined with cisplatin for treating relapsed small cell lung cancer (1990) (18)
EGFR mutation-based phase II multicenter trial of gefitinib in advanced non-small cell lung cancer (NSCLC) patients (pts): Results of West Japan Thoracic Oncology Group trial (WJTOG0403). (2006) (18)
Pharmacokinetic analysis of carboplatin and etoposide in a small cell lung cancer patient undergoing hemodialysis. (2008) (18)
[Bone metastases in lung cancer]. (2008) (18)
Establishment of tumor cell lines as an independent prognostic factor for survival time in patients with small-cell lung cancer. (1991) (18)
A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer. (2005) (18)
Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer. (2009) (18)
A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors (2013) (18)
Association of essential hypertension in elderly Japanese with I/D polymorphism of the angiotensin-converting enzyme (ACE) gene (2000) (18)
Down-regulation of survivin by ultraviolet C radiation is dependent on p53 and results in G(2)-M arrest in A549 cells. (2007) (18)
Is the Importance of Achieving Stable Disease Different between Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Cytotoxic Agents in the Second-Line Setting for Advanced Non-small Cell Lung Cancer? (2006) (18)
Myasthenia gravis induced by nivolumab in patients with non-small-cell lung cancer: a case report and literature review. (2017) (17)
Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin. (1996) (17)
Dose-intensive chemotherapy in extensive-stage small-cell lung cancer (1997) (17)
Combination chemotherapy with or without radiation therapy in small cell lung cancer. An analysis of a 5‐year follow‐up (1990) (17)
The Value of Early Depth of Response in Predicting Long‐Term Outcome in EGFR‐Mutant Lung Cancer (2018) (17)
Mathematical evaluation of 24-hour blood-pressure variability in young, middle-aged and elderly hypertensive patients. (1987) (17)
Clinical studies of irinotecan alone and in combination with cisplatin (2004) (17)
Carboplatin calculated with Chatelut's formula plus etoposide for elderly patients with small-cell lung cancer. (2001) (17)
Molecular target-based cancer therapy: tyrosine kinase inhibitors (2003) (16)
Induction therapy for stage III NSCLC: a consensus report. (1994) (16)
Sensitivity and Specificity of Lung Cancer Screening in Osaka, Japan (1991) (16)
Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): A model for prospective comparison of cooperative group trials. (2004) (16)
A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia. (2009) (16)
[A phase I study of weekly administration of CPT-11 in lung cancer]. (1990) (15)
Survivin inhibition by si-RNA induces apoptosis and increases sensitivity to adriamycin in human lung cancer cells with p53 mutation (2004) (15)
[A randomized comparative study of 254-S plus vindesine (VDS) vs. cisplatin (CDDP) plus VDS in patients with advanced non-small cell lung cancer (NSCLC)]. (1992) (15)
Efficacy of a new 5-fluorouracil derivative, BOF-A2, in advanced non-small cell lung cancer. A multi-center phase II study. (1994) (15)
Evaluation of clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open-label, first-line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P) (IPASS). (2016) (14)
Bevacizumab for non‐small‐cell lung cancer: A nested case control study of risk factors for hemoptysis (2016) (14)
Dose escalation study of carboplatin with fixed‐dose etoposide plus granulocyte‐colony stimulating factor in patients with small cell lung carcinoma: A study of the lung cancer study group of west Japan (1996) (14)
Interstitial lung disease in gefitinib-treated Japanese patients with non-small-cell lung cancer: genome-wide analysis of genetic data. (2011) (14)
[Association of indoor air pollution and passive smoking with lung cancer in Osaka, Japan]. (1990) (14)
Randomized phase III study of docetaxel (D) versus vinorelbine (V) for elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): Results of a West Japan Thoracic Oncology Group trial (WJTOG9904) (2005) (14)
[Late phase II study of LY188011 (gemcitabine hydrochloride) in patient with non-small-cell lung cancer. Gemcitabine Late Phase II Cooperative Study Group A)]. (1996) (13)
A randomized trial comparing imipenem/cilastatine alone with latamoxef plus tobramycin in febrile neutropenic patients with lung cancer. (1991) (13)
Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group. (1994) (13)
A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer (2016) (13)
Post-marketing surveillance (PMS) of all patients treated with irinotecan in Japan: clinical experience and ADR profile of 13,935 patients. (2011) (12)
Irinotecan and etoposide for previously untreated extensive-disease small cell lung cancer: a phase II trial of West Japan Thoracic Oncology Group. (2005) (12)
Sex hormones as novel risk biomarkers for atherosclerosis in peripheral vascular disease. (2007) (12)
Spontaneous pneumothorax following partial resolution of total bronchial obstruction. (1993) (12)
Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity. (2014) (12)
Effect of mandibular advancement splint on psycho-intellectual derangements in patients with sleep apnea syndrome. (1999) (12)
Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer (2006) (12)
Significance of exercise and bed rest in pregnancy--pregnancy and walking (1). (1989) (12)
Role of Chemical Mediators in Airway Hyperresponsiveness in an Asthmatic Model (2001) (12)
Large cell neuroendocrine carcinoma of the mediastinum with alpha-fetoprotein production. (2008) (12)
[Clinical effect of recombinant human G-CSF on neutropenia induced by chemotherapy for lung cancer. rG.CSF Cooperation Study Group]. (1990) (11)
Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402). (2012) (11)
Alternating non-cross resistant chemotherapy for small cell lung cancer. (1986) (11)
Increased circulating activated T-cells in lung cancer. (1986) (11)
[Studies on the appropriate administration of cisplatin based on pharmacokinetics and toxicity]. (1987) (11)
Randomized, phase III study of mitomycin/vindesine/cisplatin (MVP) versus weekly irinotecan/carboplatin (IC) or weekly paclitaxel/carboplatin (PC) with concurrent thoracic radiotherapy (TRT) for unresectable stage III non-small cell lung cancer (NSCLC): WJTOG0105. (2007) (11)
9132 POSTER Efficacy Outcomes in First-line Treatment of Advanced NSCLC With Gefitinib (G) vs Carboplatin/paclitaxel (C/P) by Epidermal Growth Factor Receptor (EGFR) Gene-copy Number Score and by Most Common EGFR Mutation Subtypes – Exploratory Data From IPASS (2011) (11)
Carcinoembryonic antigen (CEA) levels in pleural effusions and sera of lung cancer patients. (1984) (11)
9LBA Antitumor activity of ASP8273, an irreversible mutant selective EGFR-TKI, in NSCLC patients with tumors harboring EGFR activating mutations and T790M resistance mutation (2014) (11)
[A case of Sjögren's syndrome with pleural effusion]. (2000) (10)
Nested case control study of proteomic biomarkers for interstitial lung disease in Japanese patients with non-small-cell lung cancer treated with erlotinib: a multicenter phase IV study (JO21661). (2013) (10)
Disease Control as a Predictor of Survival with Gefitinib and Docetaxel in a Phase III Study (V-15-32) in Advanced Non-small Cell Lung Cancer Patients (2010) (10)
Randomized Phase II Study of Carboplatin-Paclitaxel or Gemcitabine-Vinorelbine in Patients With Advanced Nonsmall Cell Lung Cancer and a Performance Status of 2: West Japan Thoracic Oncology Group 0004 (2012) (10)
Theophylline Suppresses the Release of Interleukin-4 by Peripheral Blood Mononuclear Cells (1997) (10)
Clinical activity of ASP8273 in Asian patients with non‐small‐cell lung cancer with EGFR activating and T790M mutations (2018) (10)
[Early phase II clinical study of KW-2307 in patients with lung cancer. Lung Cancer Section in KW-2307 Study Group]. (1994) (10)
[Risk of second primary cancer in two-year survivors of small cell lung cancer]. (1996) (10)
Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer (2010) (10)
P3-148: Evaluation of efficacy and safety of erlotinib as monotherapy for Japanese patients with advanced non–small cell lung cancer (NSCLC); integrated analysis of two Japanese phase II studies (2007) (10)
A randomized phase II study of carboplatin/gemcitabine (CG) versus vinorelbine/gemcitabine (VG) in patients with advanced non-small cell lung cancer (NSCLC); mature results of West Japan Thoracic Oncology Group (WJTOG) 0104. (2004) (10)
Phase I trial of weekly docetaxel in elderly patients with non-small cell lung cancer. (2002) (10)
A randomized double-blind phase IIa dose-finding study of ZD6474 in Japanese patients with NSCLC. (2006) (10)
Phase I trial of oral 2'-deoxy-2'-methylidenecytidine: on a daily x 14-day schedule. (2000) (10)
Phase I/II study of vinorelbine, mitomycin, and cisplatin for stage IIIB or IV non-small-cell lung cancer. (1999) (9)
Histopathology of the airway epithelium in an experimental dual‐phase model of bronchial asthma (2001) (9)
A phase II study of cisplatin and irinotecan as induction chemotherapy followed by concomitant thoracic radiotherapy with weekly low-dose irinotecan in unresectable, stage III, non-small cell lung cancer: JCOG 9706. (2011) (9)
Breast metastasis from EGFR‐mutated lung adenocarcinoma: A case report and review of the literature (2018) (9)
[An early phase II study of gemcitabine hydrochloride (LY 188011). Gemcitabine Cooperative Study Group for Early Phase II]. (1996) (9)
p53 status and prognosis in stage I-IIIa non-small cell lung cancer. (1997) (9)
[Local application of anti-cancer drugs for the treatment of malignant pleural and pericardial effusion]. (1984) (9)
Neoadjuvant chemotherapy for N2 Non Small Cell Lung Cancer (1991) (9)
Phase II study of 3-hour infusion of paclitaxel in patients with previously untreated stage III and IV non-small cell lung cancer. West Japan Lung Cancer Group. (1997) (9)
[A phase II study of irinotecan combined with cisplatin in non-small cell lung cancer. CPT-11 Lung Cancer Study Group]. (2000) (9)
The Four-Arm Cooperative Study (FACS) for advanced non-small cell lung cancer (NSCLC): A subgroup analysis in elderly patients (pts) (2006) (9)
Phase I and pharmacologic study of oral (E)-2′-deoxy-2′-(fluoromethylene) cytidine: on a daily × 5-day schedule (1998) (9)
Phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in selected patients (pts) with advanced non-small cell lung cancer (NSCLC) (IPASS): Evaluation of recruits in Japan. (2016) (9)
The Four-Arm Cooperative Study (FACS) for advanced non-small cell lung cancer (NSCLC): A subgroup analysis in elderly patients (pts). (2006) (8)
Effects of saiboku-to on dual-phase bronchoconstriction in asthmatic guinea pigs. (1999) (8)
[Phase II studies of gemcitabine for non-small cell lung cancer in Japan]. (1997) (8)
Phase II study of topotecan (TOP) for relapsed small cell lung cancer (SCLC) (2000) (8)
Weekly Dose‐Intensive Chemotherapy in Patients with Small‐Cell Lung Cancer: A Pilot Study (1992) (8)
Irinotecan in small-cell lung cancer--Japanese trials. (2000) (8)
Dose escalation study of irinotecan combined with carboplatin for advanced non-small-cell lung cancer (2001) (8)
Determinants of Myelosuppression in the Treatment of Non‐small Cell Lung Cancer with Cisplatin‐containing Chemotherapy (1996) (8)
Differential expressions of cyclin A and the retinoblastoma gene product in histological subtypes of lung cancer cell lines (1997) (8)
9003 Response and progression-free survival in 1006 patients with known EGFR mutation status in phase III randomized trials of gefitinib in individuals with non-small cell lung cancer (2009) (8)
Population pharmacokinetics of erlotinib in Japanese patients with advanced non‐small cell lung cancer (2015) (8)
9002 A phase III, first-line trial of gefitinib versus cisplatin plusdocetaxel for patients with advanced or recurrent non-small cell lungcancer (NSCLC) harboring activating mutation of the epidermal growthfactor receptor (EGFR) gene: a preliminary results of WJTOG 3405 (2009) (8)
Role of muscarinic acetylcholine receptors in a guinea pig model of asthma. (2002) (8)
Three-year disease-free survivors of small cell lung cancer treated with combination chemotherapy with or without chest irradiation. (1989) (8)
Effect of anti-ICAM-1 on bronchial response: bronchoalveolar lavage fluid (BALF) and ultrastructural changes of bronchial epithelium in guinea pigs with dual phase bronchial response. (1999) (8)
切除不能な第III期非小細胞肺癌(NSCLC)に対するマイトシン/ビンデシン/シスプラチン(MVP)対毎週のイリノテカン/カルボプラチン(PC)同時併用胸部放射線療法(TRT)の無作為第III相試験:WJTOG0105 (2007) (8)
A phase I study of irinotecan in combination with amrubicin for advanced lung cancer patients. (2006) (8)
T-lymphocyte subsets in primary lung cancer. (1987) (8)
[Phase I study on DMDC]. (1996) (7)
A phase II study of induction chemotherapy (Ind CT) with CPT-11 and cisplatin followed by thoracic radiation (TRT) combined with weekly CPT-11 in patients with unresectable stage III non-small-cell lung cancer (NSCLC): A Japan Clinical Oncology (JCOG) 9706 Trial (2000) (7)
Combination therapy with bestatin in inoperable lung cancer. A randomized trial. (1990) (7)
Randomized phase III trial compared cisplatin and irinotecan (CPT-P) versus cisplatin and vindesine (VDS-P) versus irinotecan alone (CPT) in patients with advanced non-small cell lung cancer (NSCLC) — The final report (2000) (7)
Coronary Flow Reserve by Cardiac Magnetic Resonance Imaging in Patients With Diabetes Mellitus. (2019) (7)
Interleukin 6 is a cause of flu-like symptoms in treatment with a deoxycytidine analogue. (1998) (7)
[Globalization of clinical trials]. (2003) (7)
Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive stage small cell lung cancer (ED-SCLC) (final report). (2004) (7)
Phase I and pharmacologic study of weekly bolus topotecan for advanced non-small-cell lung cancer. (2010) (7)
[Prognostic factors affecting survival and response in patients with advanced non-small cell lung cancer treated with combination chemotherapy]. (1990) (7)
Role of substance P in increased airway hypersensitivity following induced stress in a guinea pig asthma model. (1998) (7)
Phase I studies of nogitecan hydrochloride for Japanese (2002) (7)
Pemetrexed-induced edema of the eyelid. (2006) (7)
A randomized phase II study of 500 mg/m2 and 1,000 mg/m2 of pemetrexed in patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had prior chemotherapy (2007) (7)
Cisplatin and etoposide chemotherapy combined with early concurrent twice-daily thoracic radiotherapy for limited-disease small cell lung cancer in elderly patients. (2010) (7)
Randomized phase II study of cisplatin , irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer ( JCOG 9902-DI ) (2003) (6)
Molecular Cancer Therapeutics Identification of cSrc as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to cSrc Inhibition (2010) (6)
[Double blind controlled study of ubenimex (Bestatin) against squamous cell lung cancer--a multicenter cooperative study]. (1993) (6)
Optimal strength and timing of steroids in the management of erlotinib-related skin toxicities in a post-marketing surveillance study (POLARSTAR) of 9909 non-small-cell lung cancer patients (2015) (6)
Safety and efficacy trial of cisplatin (P) with vinorelbine (V) followed by gefitinib (G) and concurrent thoracic radiotherapy (TRT) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC): Japan Clinical Oncology Group (JCOG) 0402. (2010) (6)
[LY188011 phase I study. Research Group of Gemcitabine (LY188011)]. (1996) (6)
Relationship between the cardiac magnetic resonance derived extracellular volume fraction and feature tracking myocardial strain in patients with non-ischemic dilated cardiomyopathy. (2020) (6)
Phase II study of recombinant human interleukin 3 administration following carboplatin and etoposide chemotherapy in small-cell lung cancer patients (1996) (6)
[A randomized controlled study of PSK combined immuno-chemotherapy for adenocarcinoma of the lung. The Advanced Lung Cancer Immuno-chemotherapy Study Group]. (1990) (6)
Phase II study of irinotecan (CPT-11) combined with etoposide (VP-16) for previously untreated extensive stage small cell lung cancer (ES-SCLC) (2000) (6)
Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non-small-cell lung cancer : Long-term follow-up results (2005) (6)
Significance of serum neuron-specific enolase as a predictor of relapse of small cell lung cancer. (1995) (6)
A phase I study of chronic daily dosing of oral etoposide in combination with cisplatin for patients with advanced cancer (1991) (6)
Phase II studies of gemcitabine for non-small cell lung cancer in Japan. (1997) (6)
Individually different "weights" of quality of life assessment in patients with advanced nonsmall-cell lung cancer. (2003) (6)
Effects of theophylline on lymphocyte phosphodiesterase activity. (1998) (6)
Phase I study of YM155, a first-in-class survivin suppressant, in patients with advanced solid tumors in Japan (2007) (6)
Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma (2019) (5)
Mitomycin C, Vindesine, and Cisplatin in Advanced Non‐Small-Cell Lung Cancer A Phase II Study (1992) (5)
[Systemic chemotherapy for brain metastasis from small cell lung cancer]. (1993) (5)
Roles of histamine receptor in a guinea pig asthma model. (1998) (5)
6560 POSTER Prognostic factors affecting survival on pretreated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) – Subgroup analysis in a randomized Ph II study of pemetrexed 500 mg/m2 and 1000 mg/m2 (2007) (5)
222 Phase II trial of topotecan for small cell lung cancer (SCLC) (1997) (5)
[The development of a new QOL Questionnaire on chemotherapy - induced emesis and vomiting--investigation of reliability and validity. Group for Investigation of QOL Questionnaire for Anti-Emetics Used in Cancer Chemotherapy. Joint Research Group for Tropisetron Double-Blind Comparative study]. (1996) (5)
Carcinoembryonic antigen in resected cases with lung cancer. Postoperative variation and recurrence. (1988) (5)
[Autopsy case of primary metastatic rhabdomyosarcoma associated with renal cancer]. (1972) (5)
Restorative effect of muroctasin on leukopenia caused by anticancer chemotherapy in lung cancer. Comparative study by envelope method. (1989) (5)
Photodynamic Therapy With YAG-OPO Laser for Early Stage Lung Cancer (1997) (5)
P-582 Dose-finding study of weekly irinotecan(CPT-11) and carboplatin (CBDCA) with concurrent thoracic radiotherapy(TRT) in locally advanced non-small cell lung cancer(NSCLC) (2003) (5)
Management of unresectable non-small cell carcinoma of the lung (NSCLC). (2003) (5)
Successful gefitinib treatment administration via gastrostomy tube in a patient with non-small cell lung cancer with dysphagia (2014) (5)
Role of topoisomerase I inhibitors in small-cell lung cancer. (2001) (5)
Redevelopment of Small‐Cell Lung Cancer Nine Years after the Start of Therapy A Case Report and Review of the Literature (1991) (5)
[Response and pharmacokinetics of cisplatin instilled into the pleural cavity]. (1985) (5)
[A phase II study of epirubicin in advanced lung cancer]. (1986) (5)
Dose-intensive chemotherapy in extensive-stage small cell lung cancer. (1994) (5)
Pain Management of Malignant Psoas Syndrome Under Epidural Analgesia During Palliative Radiotherapy (2017) (5)
[Phase-I clinical study of KW-2307 combined with cisplatin in non-small cell lung cancer patients]. (1994) (4)
A Phase I study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for Stage III non-small cell lung cancer: WJTOG 3305. (2012) (4)
9008 Clinical outcomes of bevacizumab in combination with paclitaxel/carboplatin compared with paclitaxel/carboplatin alone in previously untreated Japanese patients with advanced non-squamous non-small-cell lung cancer (NSCLC) (2009) (4)
B3-01: A randomized Phase III study to compare the overall survival of gefitinib (IRESSA) versus docetaxel in Japanese patients with previously treated advanced non-small-cell lung cancer (2007) (4)
A Phase I Study of Topotecan Plus Carboplatin for Relapsed SCLC: WJTOG Trial (2009) (4)
Late phase II trials of topotecan (T) for relapsed small cell lung cancer (SCLC) (1999) (4)
Phase I study of nimotuzumab, a humanized anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors in Japan. (2009) (4)
ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor‐naïve Japanese patients with EGFR mutation‐positive non‐small‐cell lung cancer (2018) (4)
Phase I and Pharmacokinetic Study of Combination Chemotherapy Using Irinotecan and Paclitaxel in Patients with Lung Cancer (2006) (4)
Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB–IIIA non-small cell lung cancer (WJTOG0101) (2021) (4)
Effects of suplatast tosilate (IPD Capsules) on the production of active oxygen by neutrophils and of IL-8 by mononuclear cells. (2001) (4)
486 A phase I study of pemetrexed supplemented with folic acid (FA) and vitamin b12 (VB12) in Japanese patients with solid tumors (2004) (4)
[Clinical trial of KRN 8601 in patients with neutropenia induced by chemotherapy for lung cancer]. (1990) (3)
P3-218Severe immune-related adverse events (irAE) induced by nivolumab at our institution (2017) (3)
[Phase II studies of a single agent and a cis-platinum-based two-drug combination in patients with non-small cell lung cancer]. (1988) (3)
Clinical assessment of ramosetron HCl oral preparation in the treatment of nausea and vomiting induced by cisplatin: A multicenter, randomized, parallel-design, double-blind comparative study with ondansetron HCl (2002) (3)
[Phase I clinical study of 21-consecutive-day oral administration of etoposide]. (1994) (3)
P2-274: Clinical benefits of pemetrexed 500 mg/m2 and 1000 mg/m2 in a randomized phase II study for pretreated patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) (2007) (3)
Randomized phase II study of docetaxel plus cisplatin versus docetaxel plus irinotecan in advanced non-small-cell lung cancer. A West Japan Thoracic Oncology Group Study (2000) (3)
[Early phase II study of BMS-181339 (paclitaxel) in patients with non-small cell lung cancer. BMS-181339 Non-Small Cell Lung Cancer Study Group]. (1996) (3)
A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site (2013) (3)
O1-9-2Phase I / II study of ASP8273 in patients with non-small-cell lung cancer (NSCLC) harboring EGFR activating mutations (2015) (3)
[Phase I study of raltitrexed (ZD-1694)]. (1998) (3)
Curcumin prevents and reverses murine cardiac hypertrophy. (2009) (3)
Influence of Theophylline on Activated Lymphocytes and Eosinophils in Peripheral Blood and Sputum (2001) (3)
52 Rapid and durable objective responses in patients with advanced non-small-cell lung cancer in phase II trials (IDEAL 1 and IDEAL 2) treated with gefitinib (2003) (3)
Mitomycin C, vindesine, and cisplatin in advanced non-small-cell lung cancer : a phase II study (1992) (3)
[Phase II study of cis-dichlorodiammineplatinum (II) for non-small cell lung cancer]. (1985) (3)
Current status of irinotecan in lung cancer. (2001) (3)
Phase I study of weekly docetaxel in patients with advanced refractory cancer (2000) (2)
P3-121: Phase II study of gefitinib as a first–line therapy in elderly patients with lung adenocarcinoma (WJTOG 0402–DI) (2007) (2)
A randomized phase II study of carboplatin and paclitaxel (CP) versus gemcitabine and vinorelbine (GV) in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): West Japan Thoracic Oncology Group 00 (2007) (2)
Originality benefit and difficulty of clinical research in the West Japan Lung Cancer Group. (2000) (2)
[A late phase-II trial comparing KW-2307 with vindesine in non-small cell lung cancer (1). Lung cancer section in KW-2307 Study Group]. (1995) (2)
State of the art of non-small-cell lung cancer in the new millennium. (2001) (2)
[A dose escalation study of concurrent chemoradiation therapy with nedaplatin for cervical cancer]. (2005) (2)
[Phase I clinical study on new vinca alkaloid derivative, KW-2307 (vinorelbine). KW-2307 Study Group]. (1994) (2)
[Late phase II clinical study of KW-2307 in previously untreated patients with non-small cell lung cancer. KW-2307 Study Group (Lung Cancer Group)]. (1994) (2)
GPI-anchored molecule-like protein (GML) expression in non-small cell lung cancer (NSCLC). (1999) (2)
Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E‐mutated lung adenocarcinoma (2021) (2)
Effects of saiboku-to on the survival of human eosinophils. (1999) (2)
Mass Screening for Lung Cancer in the Osaka Lung Project. (1992) (2)
[Serial measurements of serum carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) during chemotherapy of patients with inoperable lung cancer]. (1987) (2)
Spontaneous pneumothorax due to bronchopleural fistula following reirradiation for locoregionally recurrent squamous cell lung cancer (2016) (2)
Drug-induced Pneumonitis Following the Administration of TAS-102 (2016) (2)
[An early phase II clinical study of YM 294 (rhlL-11) in patients with solid tumors and malignant lymphoma]. (2005) (2)
144 Phase III study of docetaxel and irinotecan (CPT-11) for previously untreated advanced non-small cell lung cancer (NSCLC) (1997) (2)
Epoetin Beta Subcutaneous Administration to Lung Cancer Patients with Anemia; Results of Pharmacokinetics/Pharmacodynamics Study (2007) (2)
Use of hormone therapies in disseminated carcinomatosis of the bone marrow associated with hormone receptor-positive breast cancer (2018) (2)
Phase I study of weekly cisplatin (C) and docetaxel (D) in patients with inoperable non-small cell lung cancer (NSCLC) (2000) (2)
The Role of Autophagy in Iron-Overload Cardiomyopathy: A Model of Diastolic Heart Failure Due to Oxidative Stress (2009) (2)
Molecular Cancer Therapeutics Synergistic Antitumor Effect of S-1 and HER 2-Targeting Agents in Gastric Cancer with HER 2 Amplification (2010) (2)
Proposed new classification of bronchoscopic findings in lung cancer cases. (1986) (2)
Postinflammatory bronchiectatic cavity observed by fibreoptic bronchoscopy. (1994) (2)
Preliminary report of a randomized multi-center controlled study of immuno-chemotherapy versus chemotherapy in small cell lung cancer (1991) (2)
The use of granulocyte colony-stimulating factor to shorten the interval between cycles of mitomycin C, vindesine, and cisplatin chemotherapy in non-small-cell lung cancer (2004) (2)
Phase III study comparing the effects of carboplatin plus S-1 and carboplatin plus paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer: An updated report of the LETS study (WJTOG3605). (2011) (2)
[Phase I study of YNK01 (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate)]. (1990) (2)
[Phase I study of an oral administration of VP 16-213]. (1983) (2)
Abstract 4833: Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutics antibody cetuximab (2012) (2)
[Effects of an anti-emetic tropisetron capsule on QOL of patients with delayed nausea and vomiting induced by cancer chemotherapy. Group for Investigation of QOL Questionnaire for Anti-Emetics used in Cancer Chemotherapy. Joint Research Group for Tropisetron Double-Blind Comparative Study]. (1996) (2)
O-092 Randomized phase III study of docetaxel (D) versus vinorelbine (V) for elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): Results of a West Japan Thoracic Oncology Group trial (WJTOG9904) (2005) (2)
未治療の非小細胞肺癌患者に対するゲフィチニブとカルボプラチン・パクリタキセルの第III相国際共同試験（IPASS）の全生存期間最終解析 (2012) (2)
A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer (2013) (2)
O-219 Preliminary results of four arm cooperative study (FACS) for Advanced Non-Small Cell Lung Cancer (NSCLC) in Japan (2003) (2)
Low expressions of surfactant-associated protein (SP-A) in cancer tissues or in normal bronchial epithelial cells by immuno-histochemistry predict interstitial lung diseases (ILDs) induced by gefitinib in patients with advanced non-small cell lung cancer (NSCLC) (2005) (2)
W-III-6 DOSE INTENSIVE WEEKLY CODE CHEMOTHERAPY (CT) WITH OR WITHOUT rhG-CSF IN EXTENSIVE-STAGE (ES) SMALL CELL LUNG CANCER (SCLC). (1991) (2)
Combination of extracellular volume fraction by cardiac magnetic resonance imaging and QRS duration for the risk stratification for patients with non-ischemic dilated cardiomyopathy (2020) (2)
130 Phase II trial of carboplatin (CBDCA) plus oral etoposide (ETP) for elderly patients with small cell lung cancer (SCLC) (1997) (2)
Randomized phase III study of carboplatin plus S-1 compared with carboplatin plus paclitaxel as first-line chemotherapy in advanced non-small cell lung cancer (WJTOG3605). (2010) (2)
The impact of an independent response evaluation committee (REC) using RECIST guidelines in a Four-Arm Cooperative Study (FACS) for advanced non-small cell lung cancer (NSCLC) in Japan. (2004) (2)
P3-151: EGFR mutation–based phase II multicenter trial of gefitinib in patients with advanced non–small cell lung cancer (NSCLC): Results of West Japan Thoracic Oncology Group trial (WJTOG0403) (2007) (2)
Correlative study of EGFR mutations or protein expressions of EGFR, phosphorylated EGFR, HER2, phosphorylated HER2 and IGFR-1 with gefitinib sensitivity in patients with non-small cell lung cancer: Results of West Japan Thoracic Oncology Group trial (WJTOG0203A): A5-03 (2007) (2)
[Treatment of metastatic renal cell carcinoma with human lymphoblastoid interferon]. (1987) (1)
Heregulin as a novel cetuximab-resistace factor in colorectal cancer. (2010) (1)
Results of a phase I/II trial of amrubicin (AMR) in combination with cisplatin (CDDP) as a first-line treatment in patients with advanced non-small cell lung cancer (NSCLC). (2010) (1)
False-Positive Elevation of CK-MB Levels with Chest Pain in Lung Adenocarcinoma (2020) (1)
[A clinical phase III trial of ulinastatin (MR-20) for nephrotoxicity of cisplatin]. (1998) (1)
Photodynamic Therapy for Lung Cancer (1994) (1)
Serial Changes to T-cells in the Bronchial Tissue of Dual-phase Asthmatics Response Model after Allergen Challenge (1998) (1)
A phase I/II study of pemetrexed plus cisplatin in Japanese patients with malignant pleural mesothelioma (2007) (1)
Diagnostic Accuracy in Peripheral Lung Cancer Using Flexible Fiberoptic Bronchoscope (1981) (1)
A combination phase I study of amrubicin and irinotecan (CPT-11) in patients with lung cancer (2005) (1)
[High-dose Tegafur (FT) for primary lung cancer: a phase I trial]. (1991) (1)
[Therapeutic efficacy and pharmacokinetics of cisplatin in patients with non-small cell lung cancer]. (1987) (1)
[Therapeutic strategy for advanced non-small cell lung cancer]. (1995) (1)
Irinotecan in the treatment of small cell lung cancer (2001) (1)
A case of vertebral osteomyelitis and native valve endocarditis caused by Staphylococcus lugdunensis (2017) (1)
Tumor response category for the indicator of prognosis: Analysis of survival data in a Four-Arm Cooperative Study (FACS) for advanced non-small cell lung cancer (NSCLC). (2009) (1)
A phase I study of gemcitabine plus irinotecan for advanced NSCLC: Japan Clinical Oncology Group Trial (JCOG9904). (2010) (1)
[Current perspectives of new agents in lung cancer]. (2000) (1)
9117 POSTER Randomized Phase II Trial of Zoledronic Acid in Combination With Docetaxel in Previously Treated Non-small Cell Lung Cancer (NSCLC) Patients With Bone Metastases – Result of a West Japan Oncology Group Study (2011) (1)
How should we exploit TAS-102? (2018) (1)
O-272 A randomized phase II study of carboplatin/gemcitabine (CG) versus vinorelbine/gemcitabine (VG) in patients (pts) with advanced Non-Small Cell Lung Cancer (NSCLC); West Japan Thoracic Oncology Group (WJTOG) 0104 (2003) (1)
Reply to D. Tassinari et al (2009) (1)
[Restorative effect of muroctasin, MDP-Lys (L 18), on leukopenia caused by anticancer chemotherapy in lung cancer--comparative study by envelope method]. (1988) (1)
Phase II study of recombinant human interleukin 3 administration following carboplatin and etoposide chemotherapy in small-cell lung cancer patients. SDZ ILE 964 (IL-3) Study. (1996) (1)
Effect of TYB-2285 on early and late bronchial responses and airway hyperreactivity in actively sensitized guinea pigs. (1998) (1)
Catheter detachment (2015) (1)
Post-marketing surveillance of erlotinib for NSCLC in Japan: Interim analyses of 3,488 patients (Pts). (2011) (1)
A bottleneck of sputum cytology in mass survey for lung cancer: An approach to detect early stage lung cancer by sputum cytology (1982) (1)
Phase I Dose-escalation and Pharmacokinetic Trial of Lapatinib ( GW 572016 ) , a Selective Oral Dual Inhibitor of ErbB-1 and-2 Tyrosine Kinases , in Japanese Patients with Solid Tumors (2008) (1)
P-541 A phase I study of pemetrexed supplemented with folic acid (FA)and vitamin B12 (VB12) in Japanese patients with solid tumors (2005) (1)
Serum immune modulators during the first cycle of anti‐PD‐1 antibody therapy in non‐small cell lung cancer: Perforin as a biomarker (2020) (1)
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as ﬁ rst-line treatment in patients with advanced non-small-cell lung cancer (2012) (1)
A phase I study of irinotecan and carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer (2001) (1)
Correlative study of EGFR mutations or protein expressions of EGFR, phosphorylated EGFR, HER2, phosphorylated HER2 and IGFR-1 with gefitinib sensitivity in patients with non-small cell lung cancer: Results of West Japan Thoracic Oncology Group trial (WJTO) (2007) (1)
Tolerability and antitumor activity of ASP8273 in TKI-naive Japanese subjects with EGFR mutation–positive non-small cell lung cancer. (2017) (1)
1072 Phase II study of 3-hour infusion of paclitaxel in patients with previously untreated non-small cell lung cancer (NSCLC) (1995) (1)
Long term survivors in small cell lung cancer (1994) (1)
A phase I dose-escalating study of combination S-1 and carboplatin (CBDCA) in patients with chemo-naïve advanced non-small cell lung cancer (NSCLC). (2006) (1)
Studies on the variation in clinical laboratory data and safety evaluation of pharmaceuticals. (2005) (1)
Morphological Characteristics and Prognosis of the Small Size of Peripheral Squamous Cell Carcinoma of the Lung (1979) (1)
P-774 Phase II study of cisplatin plus etoposide with concurrent thoracic radiotherapy (TRT) followed by innotecan plus cisplatin in limited stage small-cell lung cancer (SCLC); A West Japan Thoracic Oncology Group Trial (2005) (1)
Double masking study of Ubenimex (bestatin) on squamous cell lung cancer (1991) (1)
[Clinical features of eight cases of opportunistic fungal pneumonias]. (1997) (1)
Abstract 3858: Synergistic antitumor effects of combination therapy with S-1 and HER2 targeting agents in gastric cancer with HER2 amplification (2010) (1)
Phase I/II trial of carboplatin (CBDCA)/ weekly paclitaxel in patients with advanced non-small cell lung cancer in Japanese population: WJTOG 9907 (2005) (1)
Percutaneous fine needle aspiration biopsy of peripheral lung lesions. (1985) (1)
Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I Study (2020) (1)
Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer. (2007) (1)
Effect of AA-2414 on Early and Late Bronchial Responses in Actively Sensitized Guinea-Pigs (2001) (1)
246 Phase I–II study of weekly irinotecan (CPT-11) combined with concurrent thoracic radiation (TRT) for locally advanced non-small-cell lung cancer (NSCLC) (1997) (1)
Porous diaphragm syndrome with recurrent thymoma (2018) (1)
A phase I/II study of carboplatin plus gemcitabine for elderly patients with advanced non-small cell lung cancer: West Japan Thoracic Oncology Group Trial (WJTOG) 2905. (2012) (1)
Phase III Study of Mitomycin/Vindesine/Cisplatin (MVP) vs. Weekly Irinotecan/Carboplatin (IC) or Weekly Paclitaxel/Carboplatin (PC) with Concurrent Thoracic Radiotherapy (TRT) for Unresectable Stage III Non–small-cell Lung Cancer (WJTOG0105); Special Reference on Delivery of TRT (2009) (1)
OA 05.03 Clinical Activity of ASP8273 in Asian Non-Small Cell Lung Cancer Patients with EGFR Activating and T790M Mutations (2017) (1)
811 Adjuvant therapy with gefitinib (‘Iressa’, ZD1839) following complete resection in Japanese patients with non-small-cell lung cancer: safety report of the first 38 patients recruited (2003) (1)
[Principles for adjuvant and neoadjuvant chemotherapy]. (1994) (1)
In Vitro Effects of Saiboku-to on Cytokine Production from Peripheral Blood Mononuclear Cells of Bronchial Asthma Patients (1999) (1)
PF2-016Treatment of TAS-102 in patients with metastatic colorectal cancer (2016) (1)
[New antitumor antimetabolites--gemcitabine and DMDC]. (1992) (1)
Abstract 1731: TAK-701, a humanized monoclonal antibody to HGF, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with anEGFRmutation (2011) (1)
O-278 Randomized phase II study of cisplatin (P), irinotecan (I), and etoposide (E) combinations administered weekly or every four weeks for extensive small cell lung cancer (ESCLC): JCOG9902-DI (2003) (1)
Correlation of Peak Expiratory Flow Rate with Exercise Tolerance in Stable Asthmatic Patients (1998) (1)
Mindin, a Regulator of Innate Immunity and Inhibitor of Angiogenesis, Contributes to Mortality and Adverse Remodeling Post Myocardial Infarction (2009) (1)
426PDEfficacy by blind independent central review (BICR): Post hoc analyses of the phase III, multicentre, randomised IPASS study of 1st-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in Asian patients (pts) with EGFR mutation-positive advanced NSCLC (2015) (1)
[Conditions suitable for chemotherapy of lung cancer]. (1983) (0)
Care cycle on advanced cancer: Reforming a value-based system. (2013) (0)
[A phase I study on a weekly schedule of DWA2114R]. (1992) (0)
P2-5-53Skin disorders caused by molecular targeted therapies in colon cancer patient (2015) (0)
[Function testing of bronchial responsiveness]. (1996) (0)
Multi-Institutio nal R andomized P hase I I T rial o f G efitinib f or Previously T reated P atients W ith A dvanced N on-Small-Cell Lung C ancer (2003) (0)
632 Immune reactions in patients with primary lung cancer: Analysis of lymphocyte subsets in bronchoalveolar lavage fluid (BALF) and peripheral blood (1997) (0)
[Current status and problems in clinical trial for new anticancer drug in Japan]. (1996) (0)
[Function testing of bronchial responsiveness]. (1997) (0)
104 Phase II study of emitefur (BOF-A2) in advanced non-small cell lung cancer (NSCLC) (1997) (0)
[Phase II study of VP-16 (capsule) in solid tumors. A cooperative study]. (1985) (0)
Serum neuron-specific enolase(s-NSE) for monitoring patients with small cell lung cancer(SCLC)during treatment. (1989) (0)
[Guideline for chemotherapy of malignant lung cancer]. (2002) (0)
[Current status of phase I and phase II trials--experience in Habikino from 1988 to 1994]. (1996) (0)
812 Randomized comparison of the antiemetic efficacy of granisetron plus methyl prednisolone sodium succinate with granisetron alone for the prevention of cisplatin-induced emesis in patients with advanced stage III non-small cell lung cancer (1997) (0)
Association of thymidylate synthase (TS) expression with response to S-1 plus carboplatin (CBDCA) in non-small cell lung cancer (NSCLC) patients (pts). (2010) (0)
243 A phase II study of the recombinant human interleukin 3 (IL-3) following carboplatin (CBDCA) and etoposide (VP-16) chemotherapy in patients with small cell lung cancer (SCLC) (1995) (0)
Nested Case Control Study of Proteomic Biomarkers for Interstitial Lung Disease in Japanese Patients With Non-Small Cell Lung Cancer Treated With Erlotinib (2012) (0)
9069 A risk–benefit analysis according to age using pooled data from two phase II trials of cisplatin plus S-1 for non-small-cell lung cancer in Japan (2009) (0)
9129 POSTER Safety Profile and Efficacy of Erlotinib in a Japanese Post-marketing Surveillance Study of 10,708 Non-small-cell Lung Cancer (NSCLC) Patients (pts) – Interim Analyses From the First 3,488 Pts (2011) (0)
P-44 Cumulative toxicity of long-term docetaxel administration in patients with solid tumors (2003) (0)
Treatment of Trochanteric Fractures (1971) (0)
TREATMENT PERIODS AND SUBJECTS IN THE COHORT AND NUMBER OF CASES AND CONTROLS IN THE NESTED CASE-CONTROL (2008) (0)
Chemotherapy versus chemo-BRM therapy in adenocarcinoma of the lung: In relation to quality of life (1991) (0)
Nd-YAG Laser Therapy for Tumors Obstructing Central Bronchi (1994) (0)
[Studies on an appropriate intra thoracic administration of cisplatin and sodium thiosulfate in malignant pleural effusion]. (1988) (0)
p 2 ! Expression as a Predictor for Favorable Prognosis in Squamous Cell Carcinoma of the Lung (2005) (0)
A phase11trial ofcombination ofCPT-1Iandcisplatin foradvancednon-small-cell lungcancer (1998) (0)
Incidence of interstitial lung disease (ILD) and risk factors for developing ILD: A final analysis of a large-scale erlotinib Japanese surveillance study in non-small-cell lung cancer (NSCLC) (2013) (0)
Phase I and pharmacokinetic study of irinotecan and paclitaxel in patients with lung cancer (2001) (0)
Disappearance of recurrent thymic epithelial tumor following corticosteroid and cyclosporine treatment: A case report. (2021) (0)
Pharmacokinetics of amrubicin in lung cancer patients with impaired hepatic function (2016) (0)
[Therapeutic strategy for small cell lung cancer]. (1997) (0)
143 Pilot study of concurrent weekly irinotecan (CPT-11) and daily carboplatin (CBDCA) with thoracic radiation therapy (TRT) in locally advanced non-small cell lung cancer (NSCLC) (1997) (0)
[Recent progress in chemotherapy for advanced lung cancer]. (1995) (0)
[Pilot study of dose intensive weekly chemotherapy followed by cisplatin plus etoposide with concurrent thoracic irradiation for limited-disease small-cell lung cancer. West Japan Thoracic Oncology Group]. (2000) (0)
Rapid detection of UGT1A1 polymorphisms by a novel microarray assay: A validation study using 100 samples from patients with lung cancer treated by irinotecan. (2016) (0)
1247 Phase I study of nimotuzumab, a humanized anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in Japanese patients with solid tumors (2009) (0)
Inhibitory Effect of an Anti‐allergic Agent, TMK‐688, on Interleukin‐2 and Interleukin‐4 Release by Mite Antigen‐stimulated Monocytes From Peripheral Blood of Asthmatic Patients (1999) (0)
Dose-escalation study of oral etoposide and carboplatin in patients with advanced lung cancer. (1996) (0)
A Case of Lung Cancer Accompaining Sarcoidosis (1986) (0)
Human C-Reactive Protein Paradoxically Protects Against Myocardial Infarction (MI) in Mice: Role of hCRP in Bone Marrow Cell Mobilization (2009) (0)
A long-term result by hyperfractionated radiotherapy with concurrent chemotherapy for limited-stage small cell lung cancer (LD-SCLC): a retrospective analysis in a single institution: P1-236 (2007) (0)
Contents, Supplement 1, 1992 (1992) (0)
Clinical studies of photodynamic therapy for roentgenographically occult lung cancer (1994) (0)
882 The usefulness of the combination of CYRFA 21-1 and proGRP (31–98) in patients with lung cancer (1997) (0)
Inhibitory effect of TMK-688 on late asthmatic responses as well as T-cell and eosinophilic infiltration in guinea pigs with asthmatic reactions. (2000) (0)
P-560 Phase I-II study of amrubicin and cisplatin as first-line treatment in patients with extensive stage small cell lung cancer (ED-SCLC) (2003) (0)
46 Phase I study of oral platinum (PT) ANALOG JM-216 given daily for 5 days☆ (1997) (0)
Phase I and Pharmacokinetics Trial of BNP7787 in Patients Receiving Cisplatin and Paclitaxel (2002) (0)
Phase I clinical study on new vinca alkaloid derivative, KW 2307 (vinorelbine) (1994) (0)
Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) using highly specific antibody against recombinant human DPD (rhDPD) in gastric scirrhous cancer treated with S-1, new DPD inhibitory fluoropyrimidine. (2006) (0)
P2-311: Randomized phase II study of carboplatin and paclitaxel (CP) versus gemcitabine and vinorelbine (GV) in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): Results of a West Japan Thoracic Oncology Group study (WJTOG0004) (2007) (0)
P2-2-72An aromatase inhibitor (AI) has led to long-term remission in a gastric cancer case with bilateral breast cancers (2015) (0)
Cardiac Complications and Changes of Arterial Blood Gas Levels during Transbronchoscopic Lung Biopsy (1981) (0)
[Study on local recurrence of squamous cell carcinoma of the lung on hilar lesion]. (1990) (0)
65 Seven Small Cell Lung Cancer (SCLC) Cell Lines established from Bronchofiberscope Biopsies (1991) (0)
19) SEQUENTIAL CHANGES OF ELECTRO-CARDIOGRAPHIC AND VECTOR-CARDIOGRAPHIC P-WAVE FORMS IN PROGRESSIVE MUSCULAR DYSTROPHY OF DUCHENNE TYPE : FOUR-YEARS' FOLLOW-UP STUDY : THE VIth CONFERENCE ON VECTORCARDIOGRAPHY (1981) (0)
PD4-2-2: Phase II study of irinotecan and S-1 combination therapy in patients (pts) with advanced non-small cell lung cancer (NSCLS): results of West Japan Thoracic Oncology Group trial (WJTOG3505) (2007) (0)
Clinical usefulness of Z-100 for the treatment of leukopenia induced by radiotherapy. A placebo-controlled double-blind raudomized trial focused on the protection of infection in lung cancer patients. (1999) (0)
COOPERATIVE RANDOMIZED STUDY OF THE TREATMENT OF SMALL CELL LUNG CANCER(SCLC) (1989) (0)
S1-5 Photodynamic Therapy (PDT) for Centrally-located Early-stage Lung Cancer(Diagnostic and Therapeutic Bronchoscopy) (1996) (0)
A combination phase I study of topotecan with carboplatin for relapsed small cell lung cancer: Results of West Japan Thoracic Oncology Group trial (WJTOG0202): P1-228 (2007) (0)
A combination phase I study of topotecan with carboplatin for relapsed small cell lung cancer: Results of West Japan Thoracic Oncology Group trial (WJTOG0202) (2007) (0)
Cisplatin, Vindesine, and Concomitant Radiation Therapy for Unresectable Non-small Cell Lung Cancer. (1991) (0)
A phase II study of irinotecan combined with cisplatin in patients with small-cell lung cancer (1994) (0)
[Current problems of early phase clinical trials for new anticancer agents in Japan]. (2000) (0)
[Phase III study--current status and problems]. (1991) (0)
P18-1 - A Case of Ischemic Cardiomyopathy Showed Postoperative Reverse Remodeling and Disappearance of Mitral Regurgitation Predicted by Late Gadolinium Enhanced MRI (2017) (0)
[Dose intensity chemotherapy in lung cancer]. (1990) (0)
Extracellular volume fraction by T1 mapping predicts omprovement of left ventricular ejection fraction after catheter ablation in patients with non-ischemic cardiomyopathy and atrial fibrillation (2020) (0)
B-22 CPT-11,A New Derivative of Camptothecin, for Patients (Pts) with Previously Treated Small Cell Lung Cancer (SCLC). (1991) (0)
Applicability of Ureteropelvic Fiberscopy in the Diagnosis of Peripheral Lung Cancer (1999) (0)
Phase II Study of the Treatment of Non-small Cell Lung Cancer with Cisplatin-carboplatin Combination Therapy. (1995) (0)
Discussion: Evaluation of Current Clinical Status and Future Directions in Small Cell Lung Cancer (1992) (0)
616 Clinical significance of P21 WAF1 CIP1 expression in non-small cell lung cancer (NSCLC) (1997) (0)
[Current results of chemotherapy in non-small cell lung cancer]. (1990) (0)
Relationship between cardiac magnetic resonance derived extracellular volume fraction and myocardial strain in patients with non-ischemic dilated cardiomyopathy (2020) (0)
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer (2022) (0)
Phase I/II study of initial high dose chemotherapy with ifosphamide/carboplatin/etoposide (ICE) followed by cisplatin/etoposide (PE) with concurrent thoracic irradiation (TRT) for limited-disease small cell lung cancer (LD-SCLC) (WJTOG9801) (2000) (0)
Abstract 216: Cathepsin-L Contributes to Ventricular Repair and Function Following Infarction through Enhanced Angiogenesis and Bone Marrow Cell Mobilization (2007) (0)
Bronchial Asthma and Immune Responses in the Respiratory Mucosa (1997) (0)
Phase II study of irinotecan and S-1 combination therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): (WJTOG3505) (2008) (0)
[Progress in diagnosis and treatment of lung cancer]. (2002) (0)
Lines Small Cell Lung Cancer Cell − Survivin Suppressant , in Non Radiosensitizing Effect of YM 155 , a Novel Small-Molecule (2008) (0)
Relationship between EGFR protein expression, EGFR gene amplification, EGFR gene mutations and gefitinib sensitivity in human non-small cell lung cancer cell lines (2006) (0)
Randomized, controlled trial of combination therapy with ubenimex (bestatin) in inoperable lung cancer (1991) (0)
[Diagnosis and treatment of lung cancer--current trends]. (1997) (0)
A phase II study of cisplatin plus S-1 in patients with carcinomas of unknown primary site. (2011) (0)
[Treatment for limited-stage small cell lung cancer (LD-SCLC)]. (2002) (0)
P-697 Supporting patients with lung cancer as multi-center co-operable clinical study Group of non-profit organization (NPO) in Japan (WJTOG) (2005) (0)
[Chemotherapy for lung cancer]. (2002) (0)
The diagnosis and treatment for multiple primary lung cancers. (1991) (0)
Phase I study of intermittent (weekly) topotecan in non small cell lung cancer (NSCLC) (2001) (0)
Randomized Phase II Trial of Zoledronic Acid in Combination with Docetaxel in Previously Treated Non-Small-Cell Lung Cancer (NSCLC) Patients with Bone Metastases: WJTOG3806 (2012) (0)
Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to ionizing radiation (2005) (0)
MIS2. lung cancer clinical (2012) (0)
P3.02b-086 ASP8273 Tolerability and Antitumor Activity in TKI-Naïve Japanese Subjects with EGFRmut+ NSCLC: Preliminary Results: Topic: EGFR Clinical (2017) (0)
Cancer Treatment in the Department of Medical Oncology: Its Role in Tumor Care (2009) (0)
P-454 Phase I/II trial of carboplatin (CBDCA)/weekly paclitaxel in patients with advanced non-small cell lung cancer in Japanese population: WJTOG 9907 (2005) (0)
Postinflammatory b bronchiectatic ccavity o observed by ffibreoptic b bronchoscopy (1994) (0)
New drugs for the treatment of lung cancer. The Tokyo Cooperative Oncology Group. (1997) (0)
E-22 Establishment of Tumor Cell Lines as An Independent Prognostic Factor in Small Cell Lung Cancer (SCLC) (1991) (0)
AUC finding study of daily carboplatin administration combined with concurrent thoracic radiotherapy for elderly non-small cell lung cancer patients (2001) (0)
205 Phase I–II study of vinorelbine (VNR), cisplatin (CDDP) and mitomycin C (MMC) in non-small cell lung cancer (NSCLC) (1997) (0)
Randomized phase II study of carboplatin and paclitaxel (CP) versus gemcitabine and vinorelbine (GV) in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): Preliminary results of West Japan Thoracic Oncology Group 0004. (2016) (0)
Serum biomarkers during the first cycle of anti-PD-1 antibody therapies in non-small cell lung cancer. (2018) (0)
[Chemotherapy for small cell lung cancer]. (1988) (0)
B-42 Expression of Glutathione S-Transferase πGene in Human Lung Cancer Cell Lines (1991) (0)
A phase I study of combination S-1 and weekly docetaxel (TXT) for advanced or recurrent gastric cancer. (2006) (0)
Development of topoisomerase I inhibitors in Japan (1997) (0)
A Cace of Diffuse Pleural Mesothelioma Demonstrated Multiple Nodularities on Chest Roentgenogram (1974) (0)
Taxane-platinum pharmacogenomic predictors of outcome in Japan-USA common arm studies in advanced non-small cell lung cancer (NSCLC): a model for testing population-related pharmacogenomics: M08-01 (2007) (0)
Mass Screening for Lung Cancer in the Osaka Lung Project. II. Results of Sputum Cytology. (1995) (0)
[A randomized control study of the antiemetic efficacy of betamethasone versus methylprednisolone]. (1986) (0)
Work Related to Investigations Right after the Marketing of Drugs in a Medical Institution: The Role of Pharmacists and the Corresponding Man Power and Cost (2003) (0)
[A case of lung cancer accompanying sarcoidosis]. (1986) (0)
Abdominal pain under immunosuppressive conditions (2016) (0)
A New Trial of Mass Survey for Lung Cancer (1979) (0)
OA23.06 Overall Survival (OS) of EGFR Mutation Positive Non-Small Cell Lung Cancer Patients: Real-World Treatment Patterns of 1,660 Japanese Patients (2017) (0)
Abstract 3733: Heregulin as a novel resistant factor for cetuximab (2010) (0)
Relation between Peak Expiratory Flow and Quality of Life in Asthmatic Patients (2001) (0)
Adoptive Transfer of Regulatory T Cells Protects Against Coxsackievirus-Induced Myocarditis (2008) (0)
O1-16-6The role of palliative care unit co-operating with regional medical systems to provide reliable patient care (2015) (0)
Phase I/II trial of doranidazole (PR-350) and concurrent thoracic radiotherapy (TRT) in patients (pts) with locally advanced (LA) non-small cell lung cancer (NSCLC). (2006) (0)
[Evidence-based practice guideline for unresectable advanced lung cancer in 2003]. (2004) (0)
Analysis of Erlotinib-Related Skin Toxicities from Japanese Post-Marketing Surveillance (Polarstar) in 9,909 Non-Small-Cell Lung Cancer (NSCLC) Patients (PTS) (2012) (0)
Cell cycle regulation and radiosensitization of TZT-1027, a novel antimicrotubule agent (2006) (0)
[Combination chemotherapy with peplomycin and carboquone (esquinon) for squamous cell carcinoma of the lung]. (1982) (0)
[Clinical evaluation of 2 mg granisetron tablet for nausea and vomiting induced by anticancer drugs including cisplatin]. (1997) (0)
["State of the art" of chemotherapy for lung cancer]. (1993) (0)
[Chemotherapy of small cell lung cancer]. (1988) (0)
Recent Progress in the Treatment of Lung Cancer (1993) (0)
P1.04-40 Serum Perforin Levels During the First Cycle of Anti-PD-1 Antibody Therapies in Non-Small Cell Lung Cancer (2019) (0)
WS1. the expansion of surgical indication in gastric colorectal cancer drug therapy (2012) (0)
A Bottleneck of Sputum Cytology in Mass Survey for Lung Cancer: An Approach to Detect Early Lung Cancer by Sputum Cytology (1981) (0)
BiomarkerAnalysesandFinalOverallSurvivalResultsFroma PhaseIII,Randomized,Open-Label,First-LineStudyofGefitinib VersusCarboplatin/PaclitaxelinClinicallySelectedPatientsWith AdvancedNon-Small-CellLungCancerinAsia(IPASS) (2011) (0)
P-962 EKB-569: An irreversible EGFR tyrosine kinase inhibitor (2005) (0)
1259 POSTER A Phase II Study of Cisplatin Plus S-1 in Patients With Carcinomas of Unknown Primary Site (2011) (0)
Measurement of cytokeratin 19 fragments as a new lung cancer marker by CYFRA 21-1 enzyme immunoassay (1994) (0)
Pilot Study of Docetaxel for Cisplatin- or Irinotecan-Refractory Non-Small Cell Lung Cancer. (2000) (0)
The Role of Cytokines in the Pathogenesis of Bronchial Asthma (1998) (0)
[Internal medicine specially addressed to oncology: its role in tumor care]. (2009) (0)
[Progress in the field of pulmonary medicine in the last 100 years: Bronchoscopy]. (2002) (0)
[Respiratory insufficiency at exertion and sudden unconsciousness (neoplastic pleurisy: lung cancer and non-bacterial endocarditis]. (1975) (0)
Study of second cancer among patients disease-free for 2 or more years after treatment of primary lung cancer. (1988) (0)
Combination chemotherapy for elderly patients with non-small cell lung cancer (1994) (0)
Amrubicin (2020) (0)
Treatment and diagnosis of lung cancer. Recent trends. (1997) (0)
HIGH-DOSE-RATE ENDOBRONCHIAL BRACHYTHERAPY FOR RADIOLOGICALLY OCCULT LUNG CANCER (1996) (0)
Advances in Brief Point Mutations of the Topoisomerase IIÂ « Gene in Patients with Small Cell Lung Cancer Treated with Etoposide 1 (2006) (0)
Weekly paclitaxel (P) in patients with advanced non-small cell lung cancer (NSCLC) (2005) (0)
E-29. Epidermal growth factor receptor tyrosine kinase inhibitors: Single agent therapy (2003) (0)
O2-3-1STRIVING FOR PALLIATIVE CARE FROM THE EARLY STAGE OF CANCER THERAPY (2014) (0)
9134 POSTER Tumour Response, Skin Rash and Health-related Quality of Life (HRQoL) – Post-hoc Data From the IPASS Study (2011) (0)
[Early diagnostic system for lung cancer]. (1980) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Masahiro Fukuoka?

Masahiro Fukuoka is affiliated with the following schools: